Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England
<p><strong>Objectives</strong> The National Health Service in England funds 12 months of weekly s.c. tocilizumab (qwTCZ) for patients with relapsing or refractory GCA. During the coronavirus disease 2019 (COVID-19) pandemic, some patients were allowed longer treatment. We sought to...
Main Authors: | Quick, V, Abusalameh, M, Ahmed, S, Alkoky, H, Bukhari, M, Carter, S, Coath, FL, Davidson, B, Doddamani, P, Dubey, S, Ducker, G, Griffiths, B, Gullick, N, Heaney, J, Holloway, A, Htut, EEP, Hughes, M, Irvine, H, Kinder, A, Kurshid, A, Lim, J, Ludwig, DR, Malik, M, Mercer, L, Mulhearn, B, Nair, JR, Patel, R, Robson, J, Saha, P, Tansley, S, TOC STOP 2022 Investigators, Mackie, SL |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Oxford University Press
2023
|
Similar Items
-
Tocilizumab (Actemra)
by: Martin Sheppard, et al.
Published: (2017-09-01) -
69: COMPARING THE OUTCOMES OF GIVING TOCILIZUMAB THEN HEMOPERFUSION, HEMOPERFUSION THEN TOCILIZUMAB, AND NO INTERVENTION IN CRITICAL SARS-COV-2 PNEUMONIA PATIENTS IN MAKATI MEDICAL CENTER
by: M.V.R. Macatangay, et al.
Published: (2022-11-01) -
Tocilizumab prescribing criteria for COVID-19 patients
by: Ayman M. Al-Qaaneh, et al.
Published: (2021-04-01) -
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
by: Neven Mohamed Sarhan, et al.
Published: (2023-04-01) -
Estudio multicéntrico no intervencional en pacientes con artritis reumatoidea tratados con tocilizumab
by: F. Montoya, et al.
Published: (2017-09-01)